Heavily pre-treated EGFR-TKI-advanced EGFR-mutant NSCLCs with high expression of PD-L1 (≥25% of tumor cells) had a better median OS (mOS) than that with low expression of PD-L1 (<25% of tumor cells) (13.3 vs. 9.9 months) after ICI therapy in a Phase II ATLANTIC study [29,55]. Here, EGFR is linked to neoplasm.